NHSA

CAR‑T therapies: “Sky‑high” CAR‑T Cancer Therapies Could Break Through in This Year’s Commercial‑Insurance Price Negotiations

China Finance China StartupsCailian Press, Healthcare, Heyuan Shengwu, NHSA, Pharmaceuticals

November 3, 2025

FreshFromChina organizes publicly available and confirmed data. If you spot an error or have a better/great reference, please let us know:
📫 [email protected]

FreshFromChina is intended as an informational tool only. Content associated with FreshFromChina is not considered opinions or advice (financial or otherwise).

Get the Freshest from China, right to your inbox

Weekly updates on 📈 trends,
💻 tech, & 🧧 finance coming out of the Middle Kingdom.

⛩ oh and it’s free! ⛩

Name *

Email *

Please do not fill in this field.

Scroll to Top